Cognition Therapeutics reports CT1812 alters Alzheimer's disease biomarkers in meta-analysis of 24 patients

COGNITION THERAPEUTICS INC

Meta-analysis of 24 participants (SHINE-A) and full SPARC dataset showed CT1812 significantly alters 28 biomarkers.
11 of 28 biomarkers are priority Alzheimer's targets; effects seen on clusterin (CLU) and prion protein (PRPN).
Pathways affected include synapse health, neuroinflammation, and amyloid-β biology, consistent with mechanism.
Data presented at AD/PD 2023 conference; management says findings strengthen understanding of CT1812's effect on Aβ oligomer-driven neurotoxicity.
Ongoing trials expected to read out in coming months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.